Second generation of drug delivery

Drug targeting is today the focus of many biotech companies applying techniques such as viral and non-viral vectors, monoclonal antibodies, enzymes that are unregulated in tumours, temperature controlled drug release, folate receptors and other techniques exploiting the difference between healthy and cancer tissue.
An effective drug delivery system (DDS) builds on two important properties:
  1. The ability to hide the active drugs or prodrugs in the blood stream, thereby avoiding uptake by the reticuloendothelial system (RES) and damage to healthy cells.
  2. The ability to target and accumulate around the malignant tumor, and to penetrate and destroy tumor cells.

The first generation of lipid based drug delivery systems for intravenous application appeared on the market almost a decade ago with the commercialization of liposomal antracyclines. As could be expected, those new drug formulations had fewer side effects than free drugs, but the tumor suppressing effect was not optimal, probably as a consequence of the lack of an active targeting and release mechanism.

The second generation is still in development and will be marketed in coming years. Focus is on active tumor targeting and drug release, and will most likely result in much more effective therapies. However, the need for protected blood transportation in the form of lipid based nanocarriers such as liposomes or other lipid/polymer formulations will still be present in most cases.
It is our belief, that LiPlasome Pharma is a very promising and competitive player among this second generation drug delivery companies, with a unique targeted and integrated discovery and delivery platform.